Valneva SE revenue breakdown overview

Valneva SE revenue for the last year amounted to 166.83 M USD, the most of which — 166.18 M USD — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines. The greatest contribution to the revenue figure was made by United States — last year it brought Valneva SE 35.64 M USD, and the year before that — -25.02 M USD.